Smart tech is about to breathe new life into a long-struggling class of medical device. Despite 50 years of study and discussion, inhaler technique and adherence remain poor among asthma and COPD patients. Pharmaceutical companies are racing to develop inhalers with sensor monitoring capabilities that could maximize medication use. The market is right on the cusp...and set to explode.
BCC Sat down with David Van Sickle, the co-founder and CEO of Propeller Health. Propeller’s sensor was recently cleared for use with AstraZeneca’s Symbicort and was declared a pack-in with Novartis’ Enerzair Breezhaler asthma medicine.
Continue reading this report plus more!
Monthly Access $9.99
Single Paper $59.99